FDA Grants Fast Track Designation to Cothera Bioscience’s Zotiraciclib for Treatment of Recurrent High-Grade Glioma with IDH1/2 Mutations
Breakthrough oral CDK9 inhibitor advances care for patients with recurrent high-grade gliomas harboring IDH1/2 mutations FOR IMMEDIATE RELEASE San Mateo, CA and Bethesda, MD —
Cothera Bioscience Announces FDA Fast Track Designation for Clinical Program PC-002
San Francisco, California, October 14, 2024 — Cothera Bioscience, a leading biotech innovator advancing clinical stage therapeutics for previously undruggable oncology targets with high unmet
Cothera Bioscience Announces Orphan Drug Designation for PC-002 for the Treatment of Burkitt Lymphoma
San Francisco December 7, 2023 – Cothera Bioscience, a clinical stage biotech company developing therapeutics for previously undruggable oncology targets with high unmet medical needs,
Cothera Announces Dosing of First Patient in Phase 2 Clinical Trial to Test Its DUB Inhibitor PC-002 for the Treatment of High-Grade B-cell Lymphoma
San Francisco, December 19, 2022–Cothera Bioscience today announced that it has dosed the first patient with PC-002, a first-in-class deubiquitinase (DUB) inhibitor, in a global
Cothera Acquires Exclusive Worldwide Rights to Zotiraciclib, a Novel Oral Multi-kinase Inhibitor from Adastra Pharmaceuticals
Beijing, San Francisco, September 7, 2021–Cothera Bioscience today announced that it has reached an agreement to acquire exclusive worldwide rights to zotiraciclib (ZTR/TG02) from Adastra
Cothera Receives Authorization from the FDA to Conduct a Phase 2 Clinical Trial to Test Its Targeted MYC Mutation Inhibitor PC-002 for the Treatment of High-Grade B-cell Lymphoma
Beijing, San Francisco, June 17, 2021–Cothera Bioscience today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to initiate a